CN101062249A - Combination of anemarrhena extract and phellodendron extract and the function thereof - Google Patents
Combination of anemarrhena extract and phellodendron extract and the function thereof Download PDFInfo
- Publication number
- CN101062249A CN101062249A CN 200710040990 CN200710040990A CN101062249A CN 101062249 A CN101062249 A CN 101062249A CN 200710040990 CN200710040990 CN 200710040990 CN 200710040990 A CN200710040990 A CN 200710040990A CN 101062249 A CN101062249 A CN 101062249A
- Authority
- CN
- China
- Prior art keywords
- extract
- rhizoma anemarrhenae
- cortex phellodendri
- supernatant
- ethanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an application of compound of timosaponin extract and phellodendron bark extract in foods and preparation of prostate hyperplasia medicine in medicine and pharmacology technical domain, which is characterized by the following: possessing saponin and chromocor chemical element in timosaponin; possessing anti-diabetes medicinal and antibiotic function; possessing alkaloid in chemical element of phellodendron bark; possessing antibiotic function; setting the sum of mango glycosides and new mango glycosides content not less than 50%; setting the content of berberine in phellodendron bark extract not less than 50%. This invention also relates to basic preparing method. This invention can be used to cure big mouse prostate hyperplasia of enarmon, which can prepare medicine to prevent and cure prostate hyperplasia.
Description
Technical field:
The present invention relates to medical technical field, be specifically related to medicine or the Application in Food of the compositions of Rhizoma Anemarrhenae extract and Cortex Phellodendri extract at preparation control prostatic hyperplasia.
Background technology:
The Rhizoma Anemarrhenae is a liliaceous plant Rhizoma Anemarrhenae Anemarrhena asphodeloides Bunge rhizome, has nourishing YIN to lower pathogenic fire, moisturizes the effect of laxation, the clinical diabetess that are used for more.When at present the Rhizoma Anemarrhenae is medicinal the unit's of being mainly Rhizoma Anemarrhenae decoction pieces or fry in shallow oil soup with other drug matchings after take.
The chemical constituent of the Rhizoma Anemarrhenae is mainly saponin and flavones ingredient.Rhizoma Anemarrhenae flavones ingredient pharmacological action report has been arranged, mainly contain: Rhizoma Anemarrhenae water extract and active component chimonin thereof and glucosides thereof have diabetes effect (foreign medical science Chinese medicine fascicle, 2002,24 (6) 353; Chinese invention patent ZL03115509.X).Rhizoma Anemarrhenae extract has antibacterial action (Plant Pathology, 2006,36 (3) 267-272; Chinese invention patent ZL200410037779.0).
Cortex Phellodendri derives from Rutaceae Phellodendron (Phdlodendron) plant, and this product beginning is stated from Shennong's Herbal, and original name " bark of a cork tree art " lists product.Conventional Chinese medicine for heat clearing and damp drying, eliminating fire and detoxication, reducing the asthenic fever.Discover that the Cortex Phellodendri chemical constituent mainly is that alkaloid is arranged.Antibiotic effect (Chinese wild plant resource, 2001,20 (4), 6 of waiting are arranged; Chinese invention patent ZL200510070578.5)
Hyperplasia of prostate (BPH) is the middle-aging male commonly encountered diseases, and data shows that prostatic hyperplasia sickness rate before 40 years old is very low, accounts for 40%, 80 years old person more than 50 years old and almost 100% suffers from this disease in the time of nearly 90%, 90 years old.Therefore, this sick active drug of research treatment is the urgent task that the world of medicine faces, and important clinical significance is arranged.The medicine that suppresses in the prior art and treat prostatic hyperplasia mainly contains based on chemicals: the anti-androgens medicine, as diethylstilbestrol, megestrol etc.; And receptor blocking agent class medicine, as phenol Bian Ming, phentolamine, hytrin etc.Above medicine all more or less has toxic and side effects to a certain degree.Certainly, also there is side effect smaller Chinese medicine to administer prostatic hyperplasia, as Lenin before Herba Saussureae Involueratae prostatitis three, the strange health etc., but their poor effect.
Still the compositions of not having at present report demonstration Rhizoma Anemarrhenae extract and Cortex Phellodendri extract has prostatic hyperplasia (hypertrophy) prevention and therapeutical effect.
Summary of the invention:
The object of the present invention is to provide medicine or the Application in Food of the compositions of Rhizoma Anemarrhenae extract and Cortex Phellodendri extract at preparation control prostatic hyperplasia.
The present invention is used to prevent and treat the medicine or the food of prostatic hyperplasia with the compositions of Rhizoma Anemarrhenae extract and Cortex Phellodendri extract, and Rhizoma Anemarrhenae extract wherein makes by the following method:
After the Rhizoma Anemarrhenae is pulverized, use 20-95% aquiferous ethanol heating extraction or soak extraction, extracting solution concentrates the centrifugal or filtration in back, abandons precipitation, and supernatant or filtrate are standby; Above-mentioned supernatant or filtrate are carried out the absorption of polystyrene porous adsorbent resin, after water drenches decontamination, use 15～25% aqueous C of 5～15 times of amount volumes of sample crude drug quality
1～C
5The lower alcohol eluting; Eluent is concentrated into does not have alcohol, leaves standstill, and separates out precipitation, and centrifugal or filtration must precipitate extract 1, and supernatant or filtrate are standby; Add the ethanol precipitate with ethanol in supernatant or filtrate, the ethanol final concentration is 70-95%, abandons precipitation, the supernatant behind the precipitate with ethanol is concentrated into dried, solids be an extract 2; Or after supernatant concentrated, spray drying, also extract 2; United extraction thing 1 and extract 2 and mix homogeneously promptly get Rhizoma Anemarrhenae extract;
Cortex Phellodendri extract wherein makes by the following method:
After Cortex Phellodendri is pulverized, extract with 40～80% aquiferous ethanol percolation, the same Rhizoma Anemarrhenae extract of all the other steps had both got Cortex Phellodendri extract.
The Rhizoma Anemarrhenae extract component analysis that obtains: through silica gel, sephadexLH-20, reversed phase chromatography carrier column chromatographies such as ODS obtain 2 chemical compounds, with chemistry, spectral method has been measured structure, is respectively: chimonin (mangiferin) and Neomangiferin (neomangiferin).Detect quantitative analysis with HPLC and show, chimonin and Neomangiferin content sum 〉=50% in the Rhizoma Anemarrhenae extract, and the content ratio of chimonin and Neomangiferin is 1: 1～5: 1.
The Cortex Phellodendri extract component analysis that obtains: through silica gel, sephadexLH-20, reversed phase chromatography carrier column chromatographies such as ODS obtain 1 chemical compound, and with chemistry, spectral method has been measured structure, for: berberine (berberine).Detect quantitative analysis with HPLC and show berberine in the Cortex Phellodendri extract 〉=50%.
Experimental result proves, behind the combination treatment of Rhizoma Anemarrhenae extract and Cortex Phellodendri extract, prostate weight in wet base and the prostate index (prostate index=prostate weight in wet base (g)/rat body weight (g) * 100) of prostatic hyperplasia rat are reduced, and effect is better than using separately Rhizoma Anemarrhenae extract or Cortex Phellodendri extract.Hypertrophy suppresses obviously after the administration of administration group prostata tissue.Therefore, Rhizoma Anemarrhenae extract and Cortex Phellodendri extract compositions can be used for preparing medicine or the food of preventing and treating prostatic hyperplasia.
The present invention has expanded new medical usage to Rhizoma Anemarrhenae extract and Cortex Phellodendri extract compositions, also provides a kind of new medicament sources for the control prostatic hyperplasia.Rhizoma Anemarrhenae extract and Cortex Phellodendri extract compositions safety and low toxicity, pharmacological action is stronger, and its raw material sources are abundant, and cheap, preparation technology is simple, can be used for preparing medicine or the food of preventing and treating prostatic hyperplasia.
The specific embodiment:
The invention will be further described below in conjunction with embodiment, but enforcement of the present invention is not limited thereto.
Embodiment 1: the Rhizoma Anemarrhenae extract preparation
Rhizoma ane marrhenae after 100 kilograms of pulverizing drops into extraction pot, uses 400 liters of heating extraction of 70% ethanol 3 times successively at 90～100 ℃, and each extraction time is 90 minutes, merges 3 times extracting solution, is concentrated into 80 liters, and filtration is adjusted to 100 liters with filtrate with distilled water.Slowly by the adsorption column of 350 liters of ZTC-1 type macroporous resins (Tianjin became the production of clarification technique company limited in positive day) is arranged, go out decontamination again with 500 liters of distilled water drip washing; 1000 liter of 20% ethanol elution of reuse collected eluent, is concentrated into 10 liters, leaves standstill 24 hours, and precipitation is separated out, and filters, and gets 0.4 kilogram of light-yellow precipitate after the drying and crushing, is extract 1; With slowly adding 100 liter of 95% ethanol under the filtrate restir, leave standstill 12 hours again, centrifugal, and the precipitation supernatant concentration is extremely dried, gets 1.6 kilograms of yellow powders after the drying and crushing, is extract 2; United extraction thing 1 and extract 2 mix homogeneously are Rhizoma Anemarrhenae extract of the present invention, weigh 2.0 kilograms altogether, are 2.0% by crude drug amount yield.
Embodiment 2: the Cortex Phellodendri extract preparation
Cortex Phellodendri medical material after 100 kilograms of pulverizing is with 80% ethanol 3: 1 (solvent volume: medical material weight) soak into that percolation extracts after 24 hours, collects 24 times and measure percolates, be extracting solution.Extracting solution is used rotating thin film concentrating instrument concentrating under reduced pressure to there not being the alcohol flavor; Concentrated solution is centrifugal, and supernatant is the upper prop sample liquid.Sample liquid is equipped with in the chromatographic column of D101 resin by the feeding of 0.8BV applied sample amount, and 95% ethanol elution of 50% ethanol of 20% ethanol of the distilled water of usefulness, 8BV, 12BV, 8BV is collected 50% ethanol elution part successively; 50% ethanol elution be evaporated to drying and pulverize yellow powder, its alkaloidal total content is more than 60%, is Cortex Phellodendri extract of the present invention.To the total alkaloids finished product, average total yield is more than 3.0% to this technology from medical material.
Embodiment 3: pharmacological activity test
Test material:
1. animal: the SD rat is provided cleaning level (animal quality certification SCXK (Shanghai) 2002-0010) by Shanghai Slac Experimental Animal Co., Ltd.
2. medicine: Rhizoma Anemarrhenae extract, Cortex Phellodendri extract are by implementing method preparation in 1,2.
3. reagent: (Shanghai General Pharmaceutical Co., ltd., 1ml/ props up the Testosterone Propionate injection, lot number: the accurate word H31020524 of traditional Chinese medicines)
Method and result:
Method:
1) animal is handled: animal model is with reference to above test method part modeling.With SD rat random packet: administration group, model contrast and blank group.Except that the blank group, other organize every rat skin lower injection Testosterone Propionate injection 3mg/ (kgd), and normal control group subcutaneous injection is made with extra care Oleum Sesami.The administration group is irritated stomach with corresponding medical material or extract respectively, and blank group and model control group are given the equivalent distilled water, 4 weeks of continuous irrigation stomach.
2) prostate weight in wet base and exponential mensuration: after irritating stomach 24h for the last time, rat is put to death in the cervical vertebra dislocation, cuts open and gets prostate, carefully separates each leaf prostate, claims the rat prostate weight in wet base with electronic balance, and calculates the prostate index.10% formalin solution is prostate fixedly, paraffin embedding, and section, histological observation is carried out in conventional H E dyeing under the mirror.
Prostate index=prostate weight in wet base (g)/rat body weight (g) * 100
3) prostata tissue is put into the gauge line that contains normal saline and measured volume.
4) data and statistical procedures: parameters represents with X ± S that all significant difference adopts software spss10.0 to carry out variance analysis.
The result:
Each administration group is to the influence of prostatic hyperplasia weight and volume
Model control group rat prostate hypertrophy is obvious, the prostate index increases, relatively has statistical significance (P＜0.01) with the blank group, Rhizoma Anemarrhenae extract group and Rhizoma Anemarrhenae extract and Cortex Phellodendri extract mixture group all can alleviate siphonal lobe prostate coefficient, but Rhizoma Anemarrhenae extract and Cortex Phellodendri extract group effect are more excellent, have statistical significance (P＜0.01) with the model control group comparing difference, suppression ratio is higher than single application Rhizoma Anemarrhenae extract.Experimental result sees Table 1.From table 2, we as can be seen, the model group volume is obviously greater than matched group volume (p＜0.01), Rhizoma Anemarrhenae extract group and Rhizoma Anemarrhenae extract and Cortex Phellodendri extract mixture group all can reduce prostate volume, but Rhizoma Anemarrhenae extract and Cortex Phellodendri extract mixture group suppression ratio are apparently higher than single application Rhizoma Anemarrhenae extract group.
Table 1 Rhizoma Anemarrhenae Cortex Phellodendri effective ingredient to the influence of weight of prostate (x ± S, n=10)
| Group | Dosage | Weight of prostate g | Prostate index g/100g body weight | Suppression ratio % |
| Matched group model group Rhizoma Anemarrhenae extract group Rhizoma Anemarrhenae extract and Cortex Phellodendri extract group | - - 400 1000 | 0.477±0.026 1.069±0.141 △△ 0.884±0.116 ** 0.777±0.135 ** | 0.143±0.016 0.347±0.046 △△ 0.281±0.046 ** 0.239±0.042 ** | - - 32.4 52.9 |
△ △P＜0.01vs blank group,
*P＜0.05,
*P＜0.01vs model control group
Each administration group of table 2 influences the prostatic hyperplasia volume
| Group | Dosage (mg/kg) | Prostate volume cm 3 | Suppression ratio % |
| Matched group model group Rhizoma Anemarrhenae extract Rhizoma Anemarrhenae extract and Cortex Phellodendri extract | - - 400 1000 | 0.479±0.036 1.174±0.140 △△0.908±0.116 **0.786±0.123 ** | - - 38.3 55.8 |
△ △P＜0.01vs blank group,
*P＜0.05,
*P＜0.01vs model control group
Claims (4)
1, the compositions of Rhizoma Anemarrhenae extract and Cortex Phellodendri extract is in the medicine or the Application in Food of preparation control prostatic hyperplasia, and Rhizoma Anemarrhenae extract wherein makes by the following method:
After the Rhizoma Anemarrhenae is pulverized, use 20-95% aquiferous ethanol heating extraction or soak extraction, extracting solution concentrates the centrifugal or filtration in back, abandons precipitation, and supernatant or filtrate are standby; Above-mentioned supernatant or filtrate are carried out the absorption of polystyrene porous adsorbent resin, after water drenches decontamination, use 15～25% aqueous C of 5～15 times of amount volumes of sample crude drug quality
1～C
5The lower alcohol eluting; Eluent is concentrated into does not have alcohol, leaves standstill, and separates out precipitation, and centrifugal or filtration must precipitate extract 1, and supernatant or filtrate are standby; Add the ethanol precipitate with ethanol in supernatant or filtrate, the ethanol final concentration is 70-95%, abandons precipitation, the supernatant behind the precipitate with ethanol is concentrated into dried, solids be an extract 2; Or after supernatant concentrated, spray drying, also extract 2; United extraction thing 1 and extract 2 and mix homogeneously promptly get Rhizoma Anemarrhenae extract;
Cortex Phellodendri extract wherein makes by the following method:
After Cortex Phellodendri is pulverized, extract with 40～80% aquiferous ethanol percolation, the same Rhizoma Anemarrhenae extract of all the other steps had both got Cortex Phellodendri extract.
2, Rhizoma Anemarrhenae extract according to claim 1 is characterized in that chimonin and Neomangiferin content sum 〉=50% in the Rhizoma Anemarrhenae extract.
3, Rhizoma Anemarrhenae extract according to claim 2 is characterized in that the content ratio of chimonin and Neomangiferin is 1: 1～5: 1 in the Rhizoma Anemarrhenae extract.
4, Cortex Phellodendri extract according to claim 1 is characterized in that content 〉=50% of berberine in the Cortex Phellodendri extract.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200710040990A CN101062249B (en) | 2007-05-22 | 2007-05-22 | Combination of anemarrhena extract and phellodendron extract and the function thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200710040990A CN101062249B (en) | 2007-05-22 | 2007-05-22 | Combination of anemarrhena extract and phellodendron extract and the function thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101062249A true CN101062249A (en) | 2007-10-31 |
| CN101062249B CN101062249B (en) | 2010-05-19 |
Family
ID=38963664
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200710040990A Expired - Fee Related CN101062249B (en) | 2007-05-22 | 2007-05-22 | Combination of anemarrhena extract and phellodendron extract and the function thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101062249B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101744978B (en) * | 2010-01-14 | 2013-07-17 | 中国科学院上海药物研究所 | Drug composition for preventing and curing diabetes mellitus |
| CN104558070A (en) * | 2013-10-14 | 2015-04-29 | 北京大学 | Chemical synthesis method of neomangiferin and intermediate compounds of neomangiferin |
| CN106420983A (en) * | 2016-11-30 | 2017-02-22 | 天津中医药大学 | Application of coptis chinensis extract in medicine for preventing and/or treating benign prostatic hyperplasia and lower urinary tract symptoms induced by benign prostatic hyperplasia |
| CN106831909A (en) * | 2016-12-29 | 2017-06-13 | 晨光生物科技集团邯郸有限公司 | The extracting method of double benzene pyrrones compounds in wind-weed fibrous root |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1203083C (en) * | 2003-02-25 | 2005-05-25 | 广州莱泰制药有限公司 | Rhizoma anemarrhenae extract and preparation process and use thereof |
| CN1695646A (en) * | 2004-05-10 | 2005-11-16 | 维奥（四川）生物技术有限公司 | Medication capsule for eliminating dampness and clearing away heat, and preparation method |
-
2007
- 2007-05-22 CN CN200710040990A patent/CN101062249B/en not_active Expired - Fee Related
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101744978B (en) * | 2010-01-14 | 2013-07-17 | 中国科学院上海药物研究所 | Drug composition for preventing and curing diabetes mellitus |
| CN104558070A (en) * | 2013-10-14 | 2015-04-29 | 北京大学 | Chemical synthesis method of neomangiferin and intermediate compounds of neomangiferin |
| CN104558070B (en) * | 2013-10-14 | 2017-10-24 | 北京大学 | The chemical synthesis process and midbody compound of Neomangiferin |
| CN106420983A (en) * | 2016-11-30 | 2017-02-22 | 天津中医药大学 | Application of coptis chinensis extract in medicine for preventing and/or treating benign prostatic hyperplasia and lower urinary tract symptoms induced by benign prostatic hyperplasia |
| CN106831909A (en) * | 2016-12-29 | 2017-06-13 | 晨光生物科技集团邯郸有限公司 | The extracting method of double benzene pyrrones compounds in wind-weed fibrous root |
| CN106831909B (en) * | 2016-12-29 | 2019-10-22 | 晨光生物科技集团邯郸有限公司 | The extracting method of double benzene pyrrones compounds in rhizoma anemarrhenae fibrous root |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101062249B (en) | 2010-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kumar et al. | Anti-diabetic activity of Syzygium cumini and its isolated compound against streptozotocin-induced diabetic rats | |
| US5589182A (en) | Compositions and method of treating cardio-, cerebro-vascular and alzheimer's diseases and depression | |
| Saeed et al. | Attenuation of biochemical parameters in streptozotocin-induced diabetic rats by oral administration of extracts and fractions of Cephalotaxus sinensis | |
| AU2004200624B2 (en) | Medicinal preparation containing phenylethanoid glycosides extracted from herbaceous plant, cistanche tubulosa (schenk.) wight, process of making the same, and uses of the same | |
| AU2003260985A1 (en) | Extraction and purification method of active constituents from stem of lonicera japonica thunb., its usage for anti-inflammatory and analgesic drug | |
| EP2161026B1 (en) | Combination of extracts from various plants to improve the symptoms of dementia | |
| CN1203083C (en) | Rhizoma anemarrhenae extract and preparation process and use thereof | |
| Gurupriya et al. | Qualitative and quantitative phytochemical analysis of Simarouba glauca leaf extract | |
| CN101062249B (en) | Combination of anemarrhena extract and phellodendron extract and the function thereof | |
| CN108653430A (en) | A kind of preparation method of the shaggy-fruited dittany extract with antitumor action | |
| CN100506259C (en) | Medicine composition for treating diabetes or diabetes kidney-disease, and preparing method | |
| CN100534508C (en) | Method for extracting effective sites group of smilax China root | |
| Pujari et al. | Anti-diabetic activity of Physagulin-F isolated from Physalis angulata fruits | |
| Osigwe et al. | Antihyperglycemic studies on the leaf extract and active fractions of Newbouldia laevis (Bignoniaceae) | |
| CN101028322B (en) | Use of Maoliefengdou extract for preparing anti-cancer medicine | |
| CN107496490A (en) | One kind extraction glycoside substance method | |
| CN100581572C (en) | Function of anemarrhena extract for preparing medicine of treating prostatic hyperplasia | |
| TWI438001B (en) | Plant extract for treating diabetes and process for making same | |
| CN111375030B (en) | Traditional Chinese medicine gel for treating skin itch | |
| CN104398950A (en) | Four-flavored calamus anticancer extract, as well as preparation method and application of four-flavored calamus anticancer extract | |
| CN104739949B (en) | Composition for Parkinson's disease and preparation method thereof | |
| Madhu et al. | Isolation and identification of Withaferin A (Steroidal Lactone) from Withania somnifera (Ashwagandha). | |
| EP1498131B1 (en) | Medicinal preparation containing phenylethanoid glycosides extracted from Cistanche tubulosa | |
| CN108653426A (en) | A kind of application of uncaria extract in preparing anti-inflammatory drug and whitening, anti-oxidant skin care item | |
| Farhana | Total Synthetic Development and Pharmacological Screening of Bioactive Isolated from Syzygium cuminii (l) Skeel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100519 |